- Home
- SRL vs MCRB Comparison
SRL vs MCRB Comparison
Compare SRL & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRL
- MCRB
- Stock Information
- Founded
- SRL 2017
- MCRB 2010
- Country
- SRL China
- MCRB United States
- Employees
- SRL N/A
- MCRB N/A
- Industry
- SRL Professional Services
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- SRL Consumer Discretionary
- MCRB Health Care
- Exchange
- SRL Nasdaq
- MCRB Nasdaq
- Market Cap
- SRL 120.1M
- MCRB 141.9M
- IPO Year
- SRL N/A
- MCRB 2015
- Fundamental
- Price
- SRL $8.00
- MCRB $0.80
- Analyst Decision
- SRL
- MCRB Buy
- Analyst Count
- SRL 0
- MCRB 4
- Target Price
- SRL N/A
- MCRB $5.63
- AVG Volume (30 Days)
- SRL 6.3K
- MCRB 875.0K
- Earning Date
- SRL 12-31-2024
- MCRB 03-04-2025
- Dividend Yield
- SRL 3.25%
- MCRB N/A
- EPS Growth
- SRL N/A
- MCRB N/A
- EPS
- SRL N/A
- MCRB N/A
- Revenue
- SRL $33,997,735.00
- MCRB $126,325,000.00
- Revenue This Year
- SRL N/A
- MCRB N/A
- Revenue Next Year
- SRL N/A
- MCRB N/A
- P/E Ratio
- SRL N/A
- MCRB N/A
- Revenue Growth
- SRL N/A
- MCRB 12856.41
- 52 Week Low
- SRL $5.74
- MCRB $0.54
- 52 Week High
- SRL $9.99
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- SRL 52.48
- MCRB 46.38
- Support Level
- SRL $7.43
- MCRB $0.81
- Resistance Level
- SRL $8.20
- MCRB $0.84
- Average True Range (ATR)
- SRL 0.28
- MCRB 0.04
- MACD
- SRL 0.02
- MCRB 0.00
- Stochastic Oscillator
- SRL 78.79
- MCRB 45.58
About SRL Scully Royalty Ltd.
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.